Basilea Pharmaceutica AG Stock price

Equities

BSLN

CH0011432447

Biotechnology & Medical Research

Real-time Estimate Cboe Europe 06:05:26 2024-03-28 am EDT 5-day change 1st Jan Change
37.6 CHF -0.40% Intraday chart for Basilea Pharmaceutica AG +5.62% +6.52%
Sales 2024 * 180M 199M Sales 2025 * 205M 226M Capitalization 453M 500M
Net income 2024 * 20M 22.06M Net income 2025 * 36M 39.71M EV / Sales 2024 * 2.83 x
Net Debt 2024 * 57.88M 63.85M Net Debt 2025 * 12.51M 13.8M EV / Sales 2025 * 2.28 x
P/E ratio 2024 *
21.8 x
P/E ratio 2025 *
13.7 x
Employees 147
Yield 2024 *
-
Yield 2025 *
-
Free-Float 91.55%
More Fundamentals * Assessed data
Dynamic Chart

Latest transcript on Basilea Pharmaceutica AG

1 day-0.40%
1 week+5.62%
Current month+6.97%
1 month+4.74%
3 months+4.16%
6 months-8.40%
Current year+6.52%
More quotes
1 week
35.60
Extreme 35.6
37.80
1 month
34.55
Extreme 34.55
38.60
Current year
32.00
Extreme 32
38.60
1 year
32.00
Extreme 32
50.50
3 years
29.55
Extreme 29.55
55.40
5 years
29.28
Extreme 29.28
61.95
10 years
29.28
Extreme 29.28
139.30
More quotes
Managers TitleAgeSince
Chief Executive Officer 59 14-08-31
Director of Finance/CFO 50 08-12-31
Chief Tech/Sci/R&D Officer 60 18-04-30
Members of the board TitleAgeSince
Director/Board Member 71 17-04-26
Director/Board Member 66 21-12-31
Director/Board Member 69 13-04-08
More insiders
Date Price Change Volume
24-03-28 37.6 -0.40% 3 674
24-03-27 37.75 +0.67% 28,753
24-03-26 37.5 +1.63% 22,909
24-03-25 36.9 +0.14% 20,891
24-03-22 36.85 +3.51% 41,895

Delayed Quote Swiss Exchange, March 28, 2024 at 05:48 am EDT

More quotes
Basilea Pharmaceutica AG Allschwil, formerly known as Basilea Pharmaceutica AG, is a Switzerland-based commercial-stage biopharmaceutical company. The Company operates in one segment, which is the discovery, development, and commercialization of pharmaceutical products to meet the needs of patients with severe bacterial and fungal infections. It launched two hospital brands, Cresemba, which is an intravenous and oral drug for the treatment of invasive fungal infections, and Zevtera, which is an intravenous antibiotic for the treatment of severe bacterial infections, especially pneumonia. Additionally, the Company has several preclinical anti-infective assets in their portfolio. Company's products are present in United States, Canada, Europe, Asia, and Africa.
Calendar
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C+
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
5
Last Close Price
37.75 CHF
Average target price
69.08 CHF
Spread / Average Target
+83.00%
Consensus
  1. Stock
  2. Equities
  3. Stock Basilea Pharmaceutica AG - Swiss Exchange